Publication

Clinical and microbiological effects of initial periodontal therapy in conjunction with amoxicillin and clavulanic acid in patients with adult periodontitis: A randomised double-blind, placebo-controlled study

Winkel, EG., van Winkelhoff, AJ., Barendregt, DS., van der Weijden, GA., Timmerman, MF. & van der Velden, U., Jul-1999, In : Journal of Clinical Periodontology. 26, 7, p. 461-468 8 p.

Research output: Contribution to journalArticleAcademicpeer-review

  • EG Winkel
  • AJ van Winkelhoff
  • DS Barendregt
  • GA van der Weijden
  • MF Timmerman
  • U van der Velden

The aim of the present study was to investigate the clinical and microbiological effects of initial periodontal therapy in conjunction with systemic amoxicillin plus clavulanic acid in adult periodontitis patients using a double-blind, parallel-group, and placebo-controlled protocol. 21 patients with a clinical diagnosis of generalised adult periodontitis were recruited. Clinical measurements and microbiological assessments were carried out at baseline, 3, and 12 months posttreatment. Approximately 6 weeks after initial periodontal treatment (3-6 h), patients were randomly assigned to receive coded study medication of 500 mg amoxicillin plus 125 mg clavulanic acid (Augmentin(R)) or placebo, every 8 h for 10 days. Patients returned for follow-up visits 3, 6, 9, and 12 months after completion of the medication. The mean plaque index (PI) at baseline was 1.1 for placebo group and 0.9 for the test group. At 3 months, the PI had dropped to 0.3 in both groups, and was maintained during the rest of the study. The changes in bleeding on probing (BOP) and gingival index (GI) in the course of the study were similar in both groups. The mean whole mouth probing pocket depth (PPD) in the placebo group was 3.8 mm at baseline and 3.9 mm in the test group. A mean reduction of 1.0 mm in the placebo group and 0.9 mm in the test group was observed during the first 3 months. No further reduction in PPD was noticed during the study period in either group. There was no statistically significant difference in the PPD reduction between the 2 groups. The change in clinical attachment level (CAL) from baseline to 3 months amounted to 0.5 mm in both groups. Between 3 and 12 months, the CAL changed in neither group. In both groups, treatment resulted in a decrease in the number of spirochetes and motile rods in positive patients, but no significant differences between either group were noted in any of the dark field microscopy observations. At baseline, 1 patient in the placebo group and 2 patients in the test group were culture positive for Actinobacillus actinomycetemcomitans (Aa). After therapy Aa was not detectable in the placebo group and 1 patient remained positive in the test group. In the placebo group, the number of patients positive for Porphyromonas gingivalis (Pg) decreased from 7 to 2 after therapy. In the test group, the 4 patients positive for Pg at baseline remained positive after therapy. In both groups, all subjects were positive for Prevotella intermedia (Pi) and Fusobacterium nucleatum (Fn) at baseline. At 12 months, all subjects had detectable subgingival Fn. 9 out of the 11 placebo and 8 of the 10 test patients remained positive for Pi. There were no differences in detection frequency of Peptostreptococcus micros (Pm) and Bacteroides forsythus (Bf) in both groups between baseline, 3, and 12 months post-treatment. The findings demonstrated that, in comparison to placebo, systemic amoxicillin plus clavulanic acid provided no additional clinical and microbiological effects in the treatment of adult periodontitis patients.

Original languageEnglish
Pages (from-to)461-468
Number of pages8
JournalJournal of Clinical Periodontology
Volume26
Issue number7
Publication statusPublished - Jul-1999

    Keywords

  • amoxicillin, clavulanic acid, double-blind, placebo-controlled, adult periodontitis, ACTINOMYCETEMCOMITANS-ASSOCIATED PERIODONTITIS, LACTAMASE-PRODUCING BACTERIA, SYSTEMIC ANTIBIOTIC-THERAPY, ACTINOBACILLUS-ACTINOMYCETEMCOMITANS, PORPHYROMONAS-GINGIVALIS, REFRACTORY PERIODONTITIS, BACTEROIDES-FORSYTHUS, TRANSPORT MEDIA, METRONIDAZOLE, DISEASE

ID: 13929684